In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide

Abstract: Objectives: To evaluate a novel series of quinoxaline 1,4-di-N-oxides for in vitro activity against Mycobacterium tuberculosis and for efficacy in a mouse model of tuberculosis (TB). Methods: Ketone and amide derivatives of quinoxaline 1,4-di-N-oxide were evaluated in in vitro and in vivo tests including: (i) activity against M. tuberculosis resistant to currently used antitubercular drugs including multidrug-resistant strains (MDR-TB resistant to isoniazid and rifampicin); (ii) activity against non-replicating persistent (NRP) bacteria; (iii) MBC; (iv) maximum tolerated dose, oral bioavailability and in vivo efficacy in mice; and (v) potential for cross-resistance with another bioreduced drug, PA-824. Results: Ten compounds were tested on single drug-resistant M. tuberculosis. In general, all compounds were active with ratios of MICs against resistant and non-resistant strains of <= 4.00. One compound, 5, was orally active in a murine model of TB, bactericidal, active against NRP bacteria and active on MDR-TB and poly drug-resistant clinical isolates (resistant to 3-5 antitubercular drugs). Conclusions: Quinoxaline 1,4-di-N-oxides represent a new class of orally active antitubercular drugs. They are likely bioreduced to an active metabolite, but the pathway of bacterial activation was different from PA-824, a bioreducible nitroimidazole in clinical trials. Compound 5 was bactericidal and active on NRP organisms indicating that activation occurred in both growing and non-replicating bacteria leading to cell death. The presence of NRP bacteria is believed to be a major factor responsible for the prolonged nature of antitubercular therapy. If the bactericidal activity and activity on non-replicating bacteria in vitro translate to in vivo conditions, quinoxaline 1,4-di-N-oxides may offer a path to shortened therapy

Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis

This study extends earlier reports regarding the in vitro efficacies of the 1,4-di-N-oxide quinoxaline derivatives against Mycobacterium tuberculosis and has led to the discovery of a derivative with in vivo efficacy in the mouse model of tuberculosis. Quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives were tested in vitro against a broad panel of single-drug-resistant M. tuberculosis strains. The susceptibilities of these strains to some compounds were comparable to those of strain H(37)Rv, as indicated by the ratios of MICs for resistant and nonresistant strains, supporting the premise that 1,4-di-N-oxide quinoxaline derivatives have a novel mode of action unrelated to those of the currently used antitubercular drugs. Specific derivatives were further evaluated in a series of in vivo assays, including evaluations of the maximum tolerated doses, the levels of oral bioavailability, and the efficacies in a low-dose aerosol model of tuberculosis in mice. One compound, ethyl 7-chloro-3-methylquinoxaline-2-carboxylate 1,4-dioxide, was found to be (i) active in reducing CFU counts in both the lungs and spleens of infected mice following oral administration, (ii) active against PA-824-resistant Mycobacterium bovis, indicating that the pathway of bioreduction/activation is different from that of PA-824 (a bioreduced nitroimidazole that is in clinical trials), and (iii) very active against nonreplicating bacteria adapted to low-oxygen conditions. These data indicate that 1,4-di-N-oxide quinoxalines hold promise for the treatment of tuberculosis

Effects Of P-mapa Immunomodulator On Toll-like Receptors And P53:potential Therapeutic Strategies For Infectious Diseases And Cancer

Background: Compounds that can act as agonists for toll-like receptors (TLRs) may be promising candidates for the development of drugs against infectious diseases and cancer. The present study aimed to characterize the immunomodulatory effects of P-MAPA on TLRs in vitro and in vivo, as well as to investigate its potential as adjuvant therapy in infectious diseases and cancer. Methods: For these purposes, the activity of P-MAPA on TLRs was assayed in vitro through NF-κB activation in HEK293 cells expressing a given TLR, and using an in vivo animal model for bladder cancer (BC). The antimicrobial activity of P-MAPA was tested against Mycobacterium tuberculosis (TB) in vitro in an MIC assay, and in vivo using an aerosol infection model of murine tuberculosis. Antitumor effects of P-MAPA were tested in an animal model with experimentally induced BC. Moxifloxacin (MXF) and Bacillus Calmette-Guerin (BCG) were used as positive controls in the animal models. Results: The results showed that P-MAPA, administered alone or in combination with MXF, induced significant responses in vivo against TB. In contrast, the compound did not show antimicrobial activity in vitro. P-MAPA showed a significant stimulatory effect on human TLR2 and TLR4 in vitro. In BC, TLR2, TLR4 and p53 protein levels were significantly higher in the P-MAPA group than in the BCG group. The most common histopathological changes in each group were papillary carcinoma in BC group, low-grade intraepithelial neoplasia in BCG group and simple hyperplasia in P-MAPA group. Concerning the toxicological analysis performed during BC treatment, P-MAPA did not show evidence for hepatotoxicity and nephrotoxicity. Conclusions: In conclusion, P-MAPA acted as TLR ligand in vitro and improved the immunological status in BC, increasing TLR2 and TLR4 protein levels. P-MAPA immunotherapy was more effective in restoring p53 and TLRs reactivities and showed significantly greater antitumor activity than BCG. The activation of TLRs and p53 may provide a hypothetical mechanism for the therapeutic effects in both cancer and infectious diseases. Taken together data obtained will encourage the further investigation of P-MAPA as a potential candidate for the treatment of cancer and infectious diseases. © 2012 Fávaro et al.; licensee BioMed Central Ltd.71Waldmann, T.A., Immunotherapy: Past, present and future (2003) Nature Medicine, 9 (3), pp. 269-277. , DOI 10.1038/nm0303-269Steinman, R.M., Mellman, I., Immunotherapy: Bewitched, bothered, and bewildered no more (2004) Science, 305 (5681), pp. 197-200. , DOI 10.1126/science.1099688Curiel, T.J., Tregs and rethinking cancer immunotherapy (2007) Journal of Clinical Investigation, 117 (5), pp. 1167-1174. , http://www.jci.org/cgi/reprint/117/5/1167, DOI 10.1172/JCI31202Murray, P.J., Aldovini, A., Young, R.A., Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines (1996) Proc Natl Acad Sci USA, 93, pp. 934-939Cook, D.N., Pisetsky, D.S., Schwartz, D.A., Toll-like receptors in the pathogenesis of human disease (2004) Nat Immunol, 5, pp. 975-995Killeen, S.D., Wang, J.H., Andrews, E.J., Redmond, H.P., Exploitation of the toll-like receptor system in cancer: A doubled-edged sword? (2006) British Journal of Cancer, 95 (3), pp. 247-252. , DOI 10.1038/sj.bjc.6603275, PII 6603275Gearing, A.J.H., Targeting toll-like receptors for drug development: A summary of commercial approaches (2007) Immunology and Cell Biology, 85 (6), pp. 490-494. , DOI 10.1038/sj.icb.7100102, PII 7100102Erard, F., Ryffel, B., Toll like receptor - Potential drug targets in infectious disease (2008) Infect Disord Drug Targets, 8, pp. 221-231Hennessy, E.J., Parker, A.E., Oneill, L.A.J., Targeting Toll-like receptors: Emerging therapeutics? (2010) Nat Rev Drug Discov, 9, pp. 293-307Akira, S., Uematsu, S., Takeuchi, O., (2006) Pathogen Recognition and Innate Immunity. Cell, 124, pp. 783-801Srikrishna, G., Freeze, H.H., Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer (2009) Neoplasia, 11, pp. 615-628Huang, B., Zhao, J., Li, H., He, K.-L., Chen, Y., Mayer, L., Unkeless, J.C., Xiong, H., Toll-like receptors on tumor cells facilitate evasion of immune surveillance (2005) Cancer Research, 65 (12), pp. 5009-5014. , DOI 10.1158/0008-5472.CAN-05-0784Kelly, M.G., Alvero, A.B., Chen, R., Silasi, D.A., Abrahams, V.M., Chan, S., Visintin, I., Mor, G., TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer (2006) Cancer Res, 66, pp. 3859-3868Paone, A., Starace, D., Galli, R., Padula, F., De Cesaris, P., Filippini, A., Ziparo, E., Riccioli, A., Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC - Dependent mechanism (2008) Carcinogenesis, 29, pp. 1334-1342Simons, M.P., O'Donnell, M.A., Griffith, T.S., Role of neutrophils in BCG immunotherapy for bladder cancer (2008) Urologic Oncology: Seminars and Original Investigations, 26 (4), pp. 341-345. , DOI 10.1016/j.urolonc.2007.11.031, PII S1078143907002980Kowalski, M., Entwistle, J., Cizeau, J., Niforos, D., Loewen, S., Chapman, W., MacDonald, G.C., A Phase i study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients (2010) Drug des Devel Ther, 4, pp. 313-320Shelley, M.D., Court, J.B., Kynaston, H., Wilt, T.J., Fish, R.G., Mason, M., (2000) Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer, p. 4Zlotta, A.R., Van Vooren, J.-P., Denis, O., Drowart, A., Daffe, M., Lefevre, P., Schandene, L., Huygen, K., What are the immunologically active components of bacille calmette-guerin in therapy of superficial bladder cancer? (2000) International Journal of Cancer, 87 (6), pp. 844-852. , DOI 10.1002/1097-0215(20000915)87:63.0.CO;2-5Perabo, F.G.E., Willert, P.L., Wirger, A., Schmidt, D.H., Von Ruecker, A., Mueller, S.C., Superantigen-activated mononuclear cells induce apoptosis in transitional cell carcinoma (2005) Anticancer Research, 25 (5), pp. 3565-3573Heldwein, K.A., Liang, M.D., Andresen, T.K., Thomas, K.E., Marty, A.M., Cuesta, N., Vogel, S.N., Fenton, M.J., TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG (2003) J Leukoc Biol, 74, pp. 277-2786Tsuji, S., Matsumoto, M., Takeuchi, O., Akira, S., Azuma, I., Hayashi, A., Toyoshima, K., Seya, T., Maturation of human dendritic cells by cell wall skeleton of Mycobacterium boris bacillus Calmette-Guérin: Involvement of toll-like receptors (2000) Infection and Immunity, 68 (12), pp. 6883-6890. , DOI 10.1128/IAI.68.12.6883-6890.2000Uehori, J., Matsumoto, M., Tsuji, S., Akazawa, T., Takeuchi, O., Akira, S., Kawata, T., Seya, T., Simultaneous blocking of human toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan (2003) Infection and Immunity, 71 (8), pp. 4238-4249. , DOI 10.1128/IAI.71.8.4238-4249.2003Oosterlinck, W., Lobel, B., Jackse, G., Malmström, P.U., Stöckle, M., Strenberg, C., European Association of Urology Recommendations 2001 Guidelines on bladder cancer (2002) Prog Urol, 12, pp. 1161-1163Tolley, D.A., Parmar, M.K.B., Grigor, K.M., Lallemand, G., Beynon, L.L., Fellows, S.J., Freedman, L.S., Whelan, P., The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of followup (1996) Journal of Urology, 155 (4), pp. 1233-1238. , DOI 10.1016/S0022-5347(01)66226-8Durán, N., Gowen, B.B., Costa, F.T., Justo, G.Z., Brocchi, M., Nunes, O.S., Nunes, I.S., A biotechnological product and its potential as a new immunomodulator for treatment of animal phlebovirus infection: Punta Toro virus (2009) Antiviral Res, 83, pp. 143-147Reis, L.O., Fávaro, W.J., Ferreira, U., Billis, A., Fazuoli, M.G., Cagnon, V.H., Evolution on experimental animal model for upper urothelium carcinogenesis (2010) World J Urol, 28, pp. 499-505Reis, L.O., Ferreira, U., Billis, A., Castello, A.Z., Nunes, I.S., Durán, N., Cagnon, V.H., Fávaro, W.J., Putative Cancer Stem Cells (CSCS) signaling after immunotherapy with Bacillus Calmette-Guerin (BCG) and P-MAPA in the Superficial Bladder Cancer (SBC) [abstract] (2011) J Urol, 185, pp. 5200-e201Nunes, I., (2008) Building A New Model for PharmaceuticalsP-MAPA, A Novel Immunomodulator Against Virus, Bacterial, and Protozoan Infections, , www.ics.trieste.it/portal/ActivityDocument.aspx?id=5711, Abstract I-8. International Centre for Science and High Technology (ICS), United Nations Industrial Development Organization (UNIDO), United Nations Industrial Development Organization Accessed atP-MAPA Immunomodulator, , http://www.farmabrasilis.org.br/todos_conteudos_interna.php?idioma= eng&id=110Bromberg, N., Justo, G.J., Seabra, A.B., Durán, N., Macrophage nitric oxide (NO) stimulation by an immunomodulator: P-MAPA (2006) Nitric Oxide-Biol Chem, 14, p. 137(2009) The Farmabrasilis Infectious Diseases Proposal -3rd Stop TB Partners Forum -Rio 2009, , http://www.farmabrasilis.org.br/pesquisa_desenvolvimento_interna.php? idioma=eng&id=255Michelsen, K.S., Aicher, A., Mohaupt, M., Hartung, T., Dimmeler, S., Kirschning, C.J., Schumann, R.R., The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2 (2001) J Biol Chem, 276, pp. 25680-25686Thoma-Uszynski, S., Kiertscher, S.M., Ochoa, M.T., Bouis, D.A., Norgard, M.V., Miyake, K., Godowski, P.J., Modlin, R.L., Activation of Toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10 (2000) Journal of Immunology, 165 (7), pp. 3804-3810Abel, B., Thieblemont, N., Quesniaux, V.J.F., Brown, N., Mpagi, J., Miyake, K., Bihl, F., Ryffel, B., Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice (2002) Journal of Immunology, 169 (6), pp. 3155-3162Barton, G.M., Medzhitov, R., Toll-like receptor signaling pathways (2003) Science, 300 (5625), pp. 1524-1525. , DOI 10.1126/science.1085536Brennan, P.J., Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis (2003) Tuberculosis, 83 (1-3), pp. 91-97. , DOI 10.1016/S1472-9792(02)00089-6Janeway, C.A., Medzhitov R: Innate immune recognition (2002) Annu Rev Immunol, 20, pp. 197-216Heine, H., Ulmer, A.J., Recognition of bacterial products by toll-like receptors (2005) Chemical Immunology and Allergy, 86, pp. 99-119Seya, T., Matsumoto, M., Tsuji, S., Begum, N.A., Nomura, M., Azuma, I., Hayashi, A., Toyoshima, K., Two receptor theory in innate immune activation: Studies on the receptors for bacillus culmet guillen-cell wall skeleton (2001) Arch Immunol Ther Exp (Warsz), 49 (SUPPL. 1), pp. 1913-S21Fricke, I., Mitchell, D., Mittelstädt, J., Lehan, N., Heine, H., Goldmann, T., Böhle, A., Brandau, S., Mycobacteria induce IFN-gamma production in human dendritic cells via triggering of TLR2 (2006) J Immunol, 176, pp. 5173-5182Ma, X., Liu, Y., Gowen, B.B., Graviss, E.A., Clark, A.G., Musser, J.M., Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease (2007) PLoS One, 2, p. 51318Reiling, N., Hölscher, C., Fehrenbach, A., Kröger, S., Kirschning, C.J., Goyert, S., Ehlers, S., Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis (2002) J Immunol, 169, pp. 3480-3484Branger, J., Leemans, J.C., Florquin, S., Weijer, S., Speelman, P., Van Der Poll, T., Toll-like receptor 4 plays a protective role in pulmonary tuberculosis in mice (2004) International Immunology, 16 (3), pp. 509-516. , DOI 10.1093/intimm/dxh052Flynn, J.L., Chan, J., Immunology of tuberculosis (2001) Annual Review of Immunology, 19, pp. 93-129. , DOI 10.1146/annurev.immunol.19.1.93Bulut, Y., Michelsen, K.S., Hayrapetian, L., Naiki, Y., Spallek, R., Singh, M., Arditi, M., Mycobacterium tuberculosis heat shock proteins use diverse toll-like receptor pathways to activate pro-inflammatory signals (2005) Journal of Biological Chemistry, 280 (22), pp. 20961-20967. , DOI 10.1074/jbc.M411379200Ayari, C., Bergeron, A., Larue, H., Ménard, C., Fradet, Y., Toll-like receptors in normal and malignant human bladders (2011) J Urol, 185, pp. 1915-1921Matijevic, T., Pavelic, J., Toll-like receptors: Cost or benefit for cancer? (2010) Curr Pharm des, 16, pp. 1081-1090Galli, R., Starace, D., Bus, R., Angelini, D.F., Paone, A., De Cesaris, P., Filippini, A., Riccioli, A., TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types (2010) J Immunol, 184, pp. 6658-6669Huang, B., Zhao, J., Shen, S., Li, H., He, K.-L., Shen, G.-X., Mayer, L., Feng, Z.-H., Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling (2007) Cancer Research, 67 (9), pp. 4346-4352. , DOI 10.1158/0008-5472.CAN-06-4067Salaun, B., Lebecque, S., Matikainen, S., Rimoldi, D., Romero, P., Toll-like receptor 3 expressed by melanoma cells as a target for therapy? (2007) Clinical Cancer Research, 13 (15), pp. 4565-4574. , http://clincancerres.aacrjournals.org/cgi/reprint/13/15/4565, DOI 10.1158/1078-0432.CCR-07-0274Salaun, B., Coste, I., Rissoan, M.C., Lebecque, S.J., Renno, T., TLR3 can directly trigger apoptosis in human cancer cells (2006) J Immunol, 176, pp. 4894-4901Khvalevsky, E., Rivkin, L., Rachmilewitz, J., Galun, E., Giladi, H., TLR3 signaling in a hepatoma cell line is skewed towards apoptosis (2007) Journal of Cellular Biochemistry, 100 (5), pp. 1301-1312. , DOI 10.1002/jcb.21119He, W., Liu, Q., Wang, L., Chen, W., Li, N., Cao, X., TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance (2007) Molecular Immunology, 44 (11), pp. 2850-2859. , DOI 10.1016/j.molimm.2007.01.022, PII S0161589007000521Xie, W., Wang, Y., Huang, Y., Yang, H., Wang, J., Hu, Z., Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells (2009) Biochem Biophys Res Commun, 379, pp. 1027-1032Goto, Y., Arigami, T., Kitago, M., Nguyen, S.L., Narita, N., Ferrone, S., Morton, D.L., Hoon, D.S., Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors (2008) Mol Cancer Ther, 7, pp. 3642-3653Zhou, M., McFarland-Mancini, M.M., Funk, H.M., Husseinzadeh, N., Mounajjed, T., Drew, A.F., Toll-like receptor expression in normal ovary and ovarian tumors (2009) Cancer Immunol Immunother, 58, pp. 1375-1385Matijevic, T., Marjanovic, M., Pavelic, J., Functionally active toll-like receptor 3 on human primary and metastatic cancer cells (2009) Scand J Immunol, 70, pp. 18-24Matijevic, T., Pavelic, J., The dual role of TLR3 in metastatic cell line (2011) Clin Exp Metastasis, 28, pp. 701-712Rakoff-Nahoum, S., Medzhitov, R., Toll-like receptors and cancer (2009) Nat Rev Cancer, 9, pp. 57-63Krieg, A.M., Development of TLR9 agonists for cancer therapy (2007) Journal of Clinical Investigation, 117 (5), pp. 1184-1194. , http://www.jci.org/cgi/reprint/117/5/1184, DOI 10.1172/JCI31414Mantovani, A., Allavena, P., Sica, A., Balkwill, F., (2008) Cancer-related Inflammation. Nature, 454, pp. 436-444Ben-Baruch, A., The multifaceted roles of chemokines in malignancy (2006) Cancer and Metastasis Reviews, 25 (3), pp. 357-371. , DOI 10.1007/s10555-006-9003-5, Special Issue on Pro-inflammatory Cytokines in CancerAllavena, P., Sica, A., Garlanda, C., Mantovani, A., The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance (2008) Immunological Reviews, 222 (1), pp. 155-161. , DOI 10.1111/j.1600-065X.2008.00607.xMalmberg, K.J., Bryceson, Y.T., Carlsten, M., Andersson, S., Björklund, A., Baumann, B.C., Fauriat, C., Ljunggren, H.G., NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy (2008) Cancer Immunol. Immunother, 57, pp. 1541-1552Proctor, M.J., Talwar, D., Balmar, S.M., O'Reilly, D.S., Foulis, A.K., Horgan, P.G., Morrison, D.S., McMillan, D.C., The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study (2010) Br J Cancer, 103, pp. 870-876Steinberg, G.D., Brendler, C.B., Ichikawa, T., Squire, R.A., Isaacs, J.T., Characterization of an N-methyl-N-nitrosourea induced autochthonous rat bladder cancer model (1990) Cancer Res, 50, pp. 6668-6741Reis, L.O., Pereira, T.C., Fávaro, W.J., Cagnon, V.H.A., Lopes-Cendes, I., Ferreira, U., Experimental animal model and RNA interference: A promising association for bladder cancer research (2009) World J Urol, 27, pp. 353-361Gunther, J.H., Jurczok, A., Wulf, T., Brandau, S., Deinert, I., Jocham, D., Bohle, A., Optimizing syngeneic orthotopic murine bladder cancer (MB49) (1999) Cancer Research, 59 (12), pp. 2834-2837Steinberg, G.D., Brendler, C.B., Squire, R.A., Isaacs, J.T., Experimental intravesical therapy for superWcial transitional cell carcinoma in a rat bladder tumor model (1991) J Urol, 145, pp. 647-653Odonnell, M.A., Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer (2005) Urol Clin North Am, 32, pp. 121-131DiPaola, R.S., Lattime, E.C., Bacillus Calmette-Guerin Mechanism of Action: The Role of Immunity, Apoptosis, Necrosis and Autophagy (2007) Journal of Urology, 178 (5), pp. 1840-1841. , DOI 10.1016/j.juro.2007.08.063, PII S0022534707020708Bohle, A., Brandau, S., Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer (2003) Journal of Urology, 170 (3), pp. 964-969. , DOI 10.1097/01.ju.0000073852.24341.4aLudwig, A.T., Moore, J.M., Luo, Y., Chen, X., Saltsgaver, N.A., O'Donnell, M.A., Griffith, T.S., Tumor necrosis factor-related apoptosis-inducing ligand: A novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity (2004) Cancer Res, 64, pp. 338-3390Pavlovich, C.P., Kraling, B.M., Stewart, R.J., Chen, X., Bochner, B.H., Luster, A.D., Poppas, D.P., O'Donnell, M.A., BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation (2000) Journal of Urology, 163 (6), pp. 2014-2021Seow, S.W., Rahmat, J.N., Mohamed, A.A., Mahendran, R., Lee, Y.K., Bay, B.H., Lactobacillus species is more cytotoxic to human bladder cancer cells than Mycobacterium bovis (bacillus Calmette-Guerin) (2002) J Urol, 168, pp. 2236-2239Berry, D.L., Blumenstein, B.A., Magyarym, D.L., Lamm, D.L., Crawford, E.D., Local toxicity patterns associated with intravesical bacillus Calmette-Guérin: A Southwest Oncology Group study (1995) Int J Urol, 3, pp. 98-101Spruck, C.H., Ohnesiet PF, Gonzalez-Zulueta M: Two molecular pathways to transitional cell carcinoma of the bladder (1994) Cancer Res, 54, pp. 784-788Levine, A.J., P53, the cellular gatekeeper for growth and division (1997) Cell, 88 (3), pp. 323-331. , DOI 10.1016/S0092-8674(00)81871-1Erill, N., Colomer, A., Verdu, M., Roman, R., Condom, E., Hannaoui, N., Banus, J.M., Puig, X., Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression (2004) Diagnostic Molecular Pathology, 13 (4), pp. 217-223. , DOI 10.1097/01.pdm.0000137098.03878.00Sarkis, A.S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z.-F., Sheinfeld, J., Fair, W.R., Herr, H.W., Reuter, V.E., Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression (1993) Journal of the National Cancer Institute, 85 (1), pp. 53-59Ahrendt, S.A., Hu, Y., Buta, M., McDermott, M.P., Benoit, N., Yang, S.C., Wu, L., Sidransky, D., P53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study (2003) Journal of the National Cancer Institute, 95 (13), pp. 961-970Wen, W.H., Press, M.F., Identification of TP53 mutations in human cancers using oligonucleotide microarrays (2004) Methods Mol Med, 97, pp. 323-335Olivier, M., Langerod, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Borresen-Dale, A.-L., The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer (2006) Clinical Cancer Research, 12 (4), pp. 1157-1167. , DOI 10.1158/1078-0432.CCR-05-1029Menendez, D., Shatz, M., Azzam, K., Garantziotis, S., Fessler, M.B., Resnick, M.A., The Toll-like receptor gene family is integrated into human DNA damage and p53 networks (2011) PLoS Genet, 7, p. 51001360Collins, L.A., Franzblau, S.G., Microplate Alamar blue assay versus BACTEC 460 system for high- throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium (1997) Antimicrobial Agents and Chemotherapy, 41 (5), pp. 1004-1009North, R.J., Izzo, A.A., Mycobacterial virulence. Virulent strains of Mycobacteria tuberculosis have faster in vivo doubling times and are better equipped to resist growth- inhibiting functions of macrophages in the presence and absence of specific immunity (1993) Journal of Experimental Medicine, 177 (6), pp. 1723-1733Lenaerts, A.J., Gruppo, V., Marietta, K.S., Johnson, C.M., Driscoll, D.K., Tompkins, N.M., Rose, J.D., Orme, I.M., Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models (2005) Antimicrobial Agents and Chemotherapy, 49 (6), pp. 2294-2301. , DOI 10.1128/AAC.49.6.2294-2301.2005Kelly, B.P., Furney, S.K., Jessen, M.T., Orme, I.M., Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis (1996) Antimicrobial Agents and Chemot

Unravelling the high-altitude Nansen blue ice field meteorite trap (East Antarctica) and implications for regional palaeo-conditions

Antarctic blue ice zones, the most productive locations for meteorite recovery on Earth, contain old ice that is easily accessible and available in large quantities. However, the mechanisms behind these meteorite traps remain a topic of ongoing debate. Here, we propose an interdisciplinary approach to improve our understanding of a meteorite trap in Dronning Maud Land (East Antarctica) on the Nansen blue ice field meteorite trap (2600–3100 m above sea level), where more than half of the Asuka meteorites have been collected. Based on 185 surface blue ice samples, one of the largest observed spatial patterns in oxygen isotopic variation to date is found. Relying on meteorites for which the terrestrial ages are determined using 14C and 36Cl, this surface ice is interpreted to date from the Last Interglacial up to the present-day. By combining state-of-the-art satellite derived surface velocities, surface mass balance modelling and ice flow modelling, we estimate that about 75–85% of the meteorites found on the ice field were supplied by ice flow after entering the ice sheet in an accumulation area of a few hundred square kilometres located south (upstream) of the ice field. Less than 0.4 new meteorites per year are supplied to the ice field through ice flow, suggesting that the hundreds of meteorites found 25 years after the first visit to this ice field mostly represent meteorites that were previously not found, rather than newly supplied meteorites. By combining these findings, the infall rate of meteorites from space is estimated, which is in line with values from the literature, but situated at the higher end of the range. A comparison of the oxygen isotopic variation of the surface blue ice to that of the European Project for Ice Coring in Antarctica (EPICA), Dronning Maud Land (EDML) ice core (located 750 km to the west, at the same elevation), suggests that the regional changes in topography have been relatively limited since the Last Interglacial, supporting theories of an overall stable East Antarctic Ice Sheet (EAIS) over this time period

Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis

This study extends earlier reports regarding the in vitro efficacies of the 1,4-di-N-oxide quinoxaline derivatives against Mycobacterium tuberculosis and has led to the discovery of a derivative with in vivo efficacy in the mouse model of tuberculosis. Quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives were tested in vitro against a broad panel of single-drug-resistant M. tuberculosis strains. The susceptibilities of these strains to some compounds were comparable to those of strain H(37)Rv, as indicated by the ratios of MICs for resistant and nonresistant strains, supporting the premise that 1,4-di-N-oxide quinoxaline derivatives have a novel mode of action unrelated to those of the currently used antitubercular drugs. Specific derivatives were further evaluated in a series of in vivo assays, including evaluations of the maximum tolerated doses, the levels of oral bioavailability, and the efficacies in a low-dose aerosol model of tuberculosis in mice. One compound, ethyl 7-chloro-3-methylquinoxaline-2-carboxylate 1,4-dioxide, was found to be (i) active in reducing CFU counts in both the lungs and spleens of infected mice following oral administration, (ii) active against PA-824-resistant Mycobacterium bovis, indicating that the pathway of bioreduction/activation is different from that of PA-824 (a bioreduced nitroimidazole that is in clinical trials), and (iii) very active against nonreplicating bacteria adapted to low-oxygen conditions. These data indicate that 1,4-di-N-oxide quinoxalines hold promise for the treatment of tuberculosis

Filling in the gaps: European governance, the open method of coordination and the European Commission

The article addresses the way in which EU policy-making operates, explains the relevance of 'lifelong learning' for the European Commission and analyses the mechanisms by which the Commission has advanced policy-making in education and training since the Lisbon Summit. The article reviews in particular the alleged lack of effectiveness of the Open Method of Coordination in education and, second, the notion that the EU advances 'slowly and persistently' in its acquisition of competences in this area